Feasibility of MRI-guided focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

Feasibility of MRI-guided focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer - MRI-guided focal salvage HDR-BT for locally recurrent prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON47701

Enrollment

Registered

2013-04-16

Start date

2013-07-11

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer recurrent prostate carcinoma

Interventions

High-dose-rate brachytherapy will be performed for patients with recurrent prostate carcinoma. The treatment will include a single fraction of 19 Gy. Salvage high-dose-rate brachytherapy will be per

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >=18 years - Biopsy proven local recurrence - Biopsy proven recurrence at least 2 years after primary radiotherapy treatment (low-dose-rate brachytherapie or external beam radiation therapy) - Limited and non-aggressive tumor presentation at time of salvage (Prostate Spedific Antigen (PSA) at time of salvage =70 - Written informed consent - Fit for spinal anaesthesia

Exclusion criteria

Exclusion criteria: - Distant metastasis - Severe toxicity during primary radiation treatment (International Prostate Symptom Score (IPSS)>15) - Patients who meet exclusion criteria for MRI following the protocol of the radiology department of the UMC Utrecht - Anticoagulant administration continuously required, except for Ascal - Discongruence between prostate biopsies and contrast MR imaging - No prior prostate cancer treatment(s) (like a recent TURP (

Design outcomes

Primary

Measure	Time frame
Incidence of grade>=3 gastro-intestinal and/or urogenital toxicity after MRI guided focal salvage therapy for locally recurrent prostate cancer. Toxicity will be determined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (National Cancer Institute).	—

Secondary

Measure	Time frame
- To determine the technical feasibility of MRI guided focal high-dose rate brachytherapy as salvage therapy for locally recurrent prostate cancer - Quality of life - Biochemical disease free survival (Phoenix criteria)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 19, 2026